The court has ordered Ranbaxy to delay launching its product until expiration of the patent in July 2016. Ranbaxy may seek to appeal this decision.
However, the court denied Pfizer’s application for a prohibition order in connection with a second patent covering a process for making amorphous atorvastatin, which also expires in July 2016.